{"schema_version":"1.0","type":"article","title":"百億美元併購新狂潮","url":"https://drugnews.com.tw/articles/2026-07-16-big-pharma-ma-new-aesthetic.html","markdown_url":"https://drugnews.com.tw/articles/2026-07-16-big-pharma-ma-new-aesthetic.md","lang":"zh-Hant","date":"2026-07-16","publish_at":"2026-07-16T08:00:00+08:00","updated_at":"2026-07-16","category":"商業分析系列","topic":"商業分析系列","tags":["商業分析系列","Big Pharma","生技併購","Vertex","Crinetics","AbbVie","Apogee Therapeutics","Novartis","Avidity Biosciences","Merck","Cidara Therapeutics","BD 授權","台灣生技"],"summary":"Vertex 以約 100 億美元收購 Crinetics，映照 Big Pharma 併購審美的轉向：不再只買規模或熱門平台，而是買細分市場統治力、技術代差與商業確定性。","key_points":[],"facts":[],"sections":["00｜大藥廠的「審美」變了","01｜百億美元新狂潮：不是亂買，而是精準狙擊","02｜第二條路：如果留在大賽道，就必須技術升維","03｜十年前的審美：規模即正義","04｜疫情後的審美：風口即正義","05｜新審美的本質：不是不買，而是只買真正差異化","06｜台灣可以怎麼看？不是追最大風口，而是做出可被國際理解的差異化","結語｜Big Pharma 的審美變了，創新藥的標準也變了","參考資料"],"references":[{"title":"[Vertex","source":"Vertex to Acquire Crinetics Pharmaceuticals, 2026-07-06]","date":"","url":"https://news.vrtx.com/node/35161/pdf"},{"title":"[Organon","source":"Sun Pharma signs Definitive Agreement to Acquire Organon, 2026-04-26]","date":"","url":"https://www.organon.com/news/sun-pharma-signs-definitive-agreement-to-acquire-organon/"},{"title":"[Eli Lilly","source":"Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders, 2026-03-31]","date":"","url":"https://investor.lilly.com/news-releases/news-release-details/lilly-acquire-centessa-pharmaceuticals-advance-treatments-sleep"},{"title":"[AbbVie","source":"AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio, 2026-06-22]","date":"","url":"https://investors.abbvie.com/news-releases/news-release-details/abbvie-acquire-apogee-therapeutics-deepening-immunology"},{"title":"[Novartis","source":"Novartis agrees to acquire Avidity Biosciences, 2025-10-26]","date":"","url":"https://www.novartis.com/news/media-releases/novartis-agrees-acquire-avidity-biosciences-innovator-rna-therapeutics-strengthening-its-late-stage-neuroscience-pipeline"},{"title":"[Merck","source":"Merck to Acquire Cidara Therapeutics, 2025-11-14]","date":"","url":"https://www.merck.com/news/merck-to-acquire-cidara-therapeutics-inc-diversifying-its-portfolio-to-include-late-phase-antiviral-agent/"},{"title":"[Pfizer","source":"Phase 3 topline results for sigvotatug vedotin in previously treated metastatic non-squamous NSCLC, 2026-06-22]","date":"","url":"https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-topline-phase-3-results-sigvotatug-vedotin"},{"title":"[FDA","source":"Voluntary withdrawal of Oxbryta from the market due to safety concerns, 2024-09-26]","date":"","url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fda-alerting-patients-and-health-care-professionals-about-voluntary-withdrawal-oxbryta-market-due"},{"title":"[FDA","source":"BESREMi prescribing information]","date":"","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761166s007lbl.pdf"},{"title":"[FDA","source":"CAMCEVI prescribing information]","date":"","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211488s010lbl.pdf"},{"title":"[Indivior","source":"Exclusive licensing agreement for Alar Pharmaceuticals' ALA-1000, 2023-10-11]","date":"","url":"https://www.indivior.com/latest/category/press-releases/2023/indivior-enters-an-exclusive-licensing-agreement-with-alar-pharmaceuticals"}],"images":[{"alt":"2026 年大型藥廠百億美元級併購，從規模競賽轉向細分市場與專科領導力","url":"https://drugnews.com.tw/assets/articles/big-pharma-ma-new-aesthetic/facebook-01.webp"},{"alt":"留在免疫、神經肌肉與感染等大賽道的藥廠，改以長效抗體、AOC 與 DFC 取得代際差異","url":"https://drugnews.com.tw/assets/articles/big-pharma-ma-new-aesthetic/facebook-02.webp"},{"alt":"Big Pharma 併購審美從規模崇拜、風口崇拜，走向差異化與確定性","url":"https://drugnews.com.tw/assets/articles/big-pharma-ma-new-aesthetic/facebook-03.webp"},{"alt":"藥華藥、逸達與昱展新藥分別以專科市場、長效製劑與明確臨床需求建立差異化","url":"https://drugnews.com.tw/assets/articles/big-pharma-ma-new-aesthetic/facebook-04.webp"}],"cover_image":"https://drugnews.com.tw/assets/articles/big-pharma-ma-new-aesthetic/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-07-16）。百億美元併購新狂潮。https://drugnews.com.tw/articles/2026-07-16-big-pharma-ma-new-aesthetic.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-07-16-big-pharma-ma-new-aesthetic-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}